** Drug developer Keros Therapeutics' KROS.O shares rise 3.6% to $58.78

** KROS says it entered into a global license agreement with Takeda 4502.T for experimental drug elritercept

** Elritercept is being developed to treat low blood cell counts in patients with myelodysplastic syndrome and myelofibrosis, which are blood cancers

** KROS to receive $200 mln upfront and potentially over $1.1 bln in milestone payments from Takeda

** Upfront payment will extend KROS' operational runway into Q4 2028, co says

** Brokerage Truist Securities believes the partnership eases concerns about KROS’s ability to commercialize in different areas

** Brokerage Guggenheim Securities says the partnership allows Keros to focus on the development of cibotercept for the treatment of pulmonary arterial hypertension

** The agreement excludes commercialization in mainland China, Hong Kong, and Macau

** All 15 brokerages rate the stock "buy" or higher; their median PT is $92 - LSEG

** Including session's gains, stock has risen 43.4% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))